# Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF

Study · id `cardio:ct-nct07169981` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07169981](<https://clinicaltrials.gov/study/NCT07169981>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07169981

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT07169981. Randomized; double masking; primary purpose treatment. Start 2023-07-12 (actual); primary completion 2025-02-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT07169981, source copy `cardio:ctgov-nct07169981-2025-09-12`, retrieved 2026-10-26)
- Started: 2023-07-12 (actual) (ClinicalTrials.gov record NCT07169981, source copy `cardio:ctgov-nct07169981-2025-09-12`, retrieved 2026-10-26)
- Primary completion: 2025-02-23 (actual) (ClinicalTrials.gov record NCT07169981, source copy `cardio:ctgov-nct07169981-2025-09-12`, retrieved 2026-10-26)
- Completion: 2025-06-17 (actual) (ClinicalTrials.gov record NCT07169981, source copy `cardio:ctgov-nct07169981-2025-09-12`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07169981, source copy `cardio:ctgov-nct07169981-2025-09-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07169981-2025-09-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
- Acronym: EMPA-DMMI
- Condition: Diabete Mellitus
- Condition: Heart Failure
- Condition: Remodeling, Left Ventricle
- Intervention (Drug): Empagliflozin 10 MG \[Jardiance\]
- Intervention (Drug): empagliflozin (Jardiance) 25 mg
- Lead sponsor: Ain Shams University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (Jardiance) (`cardio:jardiance`)
- Registry intervention name is a brand that an FDA record in the corpus ties to this substance: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Ain Shams University (`cardio:org-ain-shams-university`)

## Provenance

Content hash: 41e75ebcfb76b008d4de956c574615de946613acb4d569f0b6d3ab52206dbfdc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
